Highlights
Launch of marketing in the United States of UZEDY® (risperidone) by Teva Pharmaceuticals (“Teva”), first product using Medincell’s BEPO® technology
Successful commercial launch and negotiations with American private and public health insurance systems for market access
Receipt of a milestone payment of €3.6 million for approval by the US FDA and €1.7 million in royalties on first net sales
Sales ramp-up in line with forecasts: $80 million in revenue for the year 2024 anticipated by Teva
Acceleration of the phase 3 clinical trial of mdc-TJK (olanzapine, schizophrenia), second antipsychotic developed with Teva
End of recruitment in January 2024, i.e. 9 months earlier than initially planned
Post-closing
Announcement of positive effectiveness results in May 2024
No cases of post-injection delirium/sedation syndrome (PDSS) observed after administration of approximately 80% of the number of injections required by the FDA, as of May 8, 2024
End of phase 3 clinical trial of mdc-CWM (intra-articular celecoxib, post-operative pain, developed in partnership with AIC)
End of recruitment of 151 patients in August 2023
Post-closing
Announcement in May 2024 of encouraging phase 3 results paving the way for future developments
Funding